Peptides / Brain and mood

Synthetic fragment · 3 amino acids · 418.4 Da

Pinealon

Not approved

Pinealon is a short synthetic peptide (Glu-Asp-Arg) from the Khavinson bioregulator family, not approved as a drug. Most studies are in animals and lab cells, on the brain and memory, with a few small studies in people. PepBank shows 3 results on Pinealon from 2 studies in people, and 33 from animal and lab studies. The strongest evidence is a trial in people without random groups. Data as of 2026-10-30.

Also known as EDR, Glu-Asp-Arg

3 amino acids, from first to lastEDR

Evidence level: Mostly animal studies33 of 36 results come from studies in animals and lab cells. 2 studies in people.

Results in people

8% of 36 results

Results in animals

58% of 36 results

Results in lab cells

33% of 36 results

From computer models

0% of 36 results

Overview

Pinealon at a glance

What it is	Synthetic fragment, 3 amino acids
Approval	Not approved for any use
In sport	Status unknown
Studies	18 studies with results. 12 of them gave Pinealon, with 36 results. 3 in people21 in animals12 in lab cells
Best study in people	Non-randomized trial with 32 people (2015)
Clinical trials	None registered
Community use	Community cognitive use

The science

What is Pinealon?

Synthetic Glu-Asp-Arg tripeptide from the Khavinson bioregulator family.

Amino acids in one chain

Pinealon structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 3 amino acidsFrom the first amino acid to the last

−E1−D+R

Darker means more water-repelling+ and − show charge in the body

Structure

Pinealon is a synthetic fragment of 3 amino acids, with no ring, no changed amino acids.

Formula

C₁₅H₂₆N₆O₈

Molecular weight

418.4 g/mol

CAS number

175175-23-2

Development

Highest phase: no known clinical development.

Identifiers

PubChem 10273502

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Glu-Asp-Arg-OH

InChIKey
QPRZKNOOOBWXSU-CIUDSAMLSA-N

SMILES
C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)CN=C(N)N

See charge, composition and 3D structure on the Scientific page

The evidence

What Pinealon studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies33 of 36 results come from studies in animals and lab cells. 2 studies in people.

Cells, genes and aging

8 results · 2 in people · 2 animal · 4 lab

In patients with several illnesses, Pinealon showed a less visible effect on aging than Vesugen. Advances in gerontology = Uspekhi gerontologii, 2015

Top results

In patients with several illnesses, Pinealon showed a less visible effect on aging than Vesugen. (Advances in gerontology = Uspekhi gerontologii, 2015)
In rats exposed to prenatal hyperhomocysteinemia, maternal Pinealon treatment reduced reactive oxygen species accumulation in isolated offspring cerebellar neurons. (International journal of clinical and experimental medicine, 2012)
In cells, Pinealon reduced reactive oxygen species accumulation in stressed cerebellar granule cells in a dose-dependent manner. (Rejuvenation research, 2011)

Overall treatment results

1 result · 1 in people

In locomotive brigade workers, Pinealon improved indicators of adaptation. Advances in gerontology = Uspekhi gerontologii, 2012

Top results

In locomotive brigade workers, Pinealon improved indicators of adaptation. (Advances in gerontology = Uspekhi gerontologii, 2012)

Brain and nerves

13 results · 10 animal · 3 lab

In rats exposed to prenatal hyperhomocysteinemia, maternal Pinealon treatment reduced necrotic cells among isolated offspring cerebellar neurons. International journal of clinical and experimental medicine, 2012

Top results

In rats exposed to prenatal hyperhomocysteinemia, maternal Pinealon treatment reduced necrotic cells among isolated offspring cerebellar neurons. (International journal of clinical and experimental medicine, 2012)
In rats, Pinealon before carotid artery occlusion reduced motivational behavior. (Advances in gerontology = Uspekhi gerontologii, 2011)
In cells, Pinealon reduced necrotic cell death measured with a dye test. (Rejuvenation research, 2011)

Memory and thinking

4 results · 4 animal

In rats exposed to prenatal hyperhomocysteinemia, maternal Pinealon treatment improved offspring spatial orientation. International journal of clinical and experimental medicine, 2012

Top results

In rats exposed to prenatal hyperhomocysteinemia, maternal Pinealon treatment improved offspring spatial orientation. (International journal of clinical and experimental medicine, 2012)
In rats, Pinealon improved maze learning more than Cortexin. (Advances in gerontology = Uspekhi gerontologii, 2013)
In rats, Pinealon before carotid artery occlusion reduced position-finding behavior. (Advances in gerontology = Uspekhi gerontologii, 2011)

Daily life and fitness

1 result · 1 animal

In rats, Pinealon before carotid artery occlusion reduced motor performance. Advances in gerontology = Uspekhi gerontologii, 2011

Top results

In rats, Pinealon before carotid artery occlusion reduced motor performance. (Advances in gerontology = Uspekhi gerontologii, 2011)

Immune system and inflammation

1 result · 1 animal

In rats with hypoxic hypoxia, the study suggested that Pinealon reduced brain inflammation to a reference level. Advances in gerontology = Uspekhi gerontologii, 2014

Top results

In rats with hypoxic hypoxia, the study suggested that Pinealon reduced brain inflammation to a reference level. (Advances in gerontology = Uspekhi gerontologii, 2014)

All 2 studies in people

In people

In patients with several illnesses, Pinealon showed a less visible effect on aging than Vesugen.

2015Advances in gerontology = Uspekhi gerontologii32 people

In people

In locomotive brigade workers, Pinealon improved biological age parameters.

2012Advances in gerontology = Uspekhi gerontologii

All 18 Pinealon studies by area Open the Scientific page

Key Pinealon studies

Studies in people come first, then studies in animals and in the lab.

People
[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]
Meshchaninov et al. 2015 · Advances in gerontology = Uspekhi gerontologii · 32 people · cited by 1
1 result
People
[Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades]
Nazimko et al. 2012 · Advances in gerontology = Uspekhi gerontologii · cited by 0
2 results
Animals
Pinealon protects the rat offspring from prenatal hyperhomocysteinemia
Arutjunyan et al. 2012 · International journal of clinical and experimental medicine · cited by 15
4 results
Animals
[Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon]
Mendzheritskiĭ et al. 2014 · Advances in gerontology = Uspekhi gerontologii · cited by 3
2 results
Animals
[Effect of peptide geroprotectors on the navigation system learning and caspase-3 in brain structures in rats of different age]
Mendzheritski et al. 2013 · Advances in gerontology = Uspekhi gerontologii · cited by 1
1 result

All 18 Pinealon studies

Pinealon clinical trials

ClinicalTrials.gov lists no trial of Pinealon. A trial under another name may exist.

Status and safety

Is Pinealon approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Not recorded

Status unknown.

No. Not approved for any use. The sources we use show no clinical development. They show no approval at the FDA, the EMA or elsewhere (as of 13 Oct 2026). Status unknown.

Laws and labels change, so check the regulator for the current status.

Pinealon side effects and safety

PepBank has no safety result from studies of Pinealon yet. That does not mean Pinealon is safe.

Doses studied (1 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
1 capsule containing 100 mkg of Pinealon 2 times a day	Human	human	Not reported	two weeks	Trial in people without random groups	Nazimko 2012

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The source reports this use pattern. It does not establish safety or efficacy.

Reported routines and cautions

What people use it for

Community cognitive useS1

Reported regimens

Regimens that community sources report for Pinealon. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Community cognitive use	subcutaneous injection	100 to 300 mcg per dose	once daily	10 to 20 days, every 3 to 6 months	Single source. The site denies vendor affiliations and lists suppliers.	S1

Community sources

S1Pinealon community protocols (opens in a new tab)www.peptideprotocolwiki.com

Gaps

Single-source report. Product identity, actual use and product purity were not independently tested.

Questions and more

Ask a question about Pinealon

The answer links to every study it uses.

What does the evidence say about Pinealon?Is Pinealon tested in people?Compare with Cerebrolysin Compare with Cortexin (cortical polypeptide complex)

Sources

Database: PepBank data for Pinealon (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about Pinealon

Curo sells Pinealon. PepBank and Curo have the same owner. See Pinealon at Curo (opens in a new tab).

Pinealon

Not approved

Also known as EDR, Glu-Asp-Arg

What it is

Synthetic fragment, 3 amino acids

Approval

Not approved for any use

In sport

Status unknown

Studies

18 studies with results. 12 of them gave Pinealon, with 36 results.
3 in people21 in animals12 in lab cells

Best study in people

Non-randomized trial with 32 people (2015)

Clinical trials

None registered

Community use

Community cognitive use

Dose as reported

Class

Species

Route

Duration

Design

Source

1 capsule containing 100 mkg of Pinealon 2 times a day

Human

human

Not reported

two weeks

Trial in people without random groups

Nazimko 2012

Context

Route

Amount

How often

How long

Agreement

Sources

Community cognitive use

subcutaneous injection

100 to 300 mcg per dose

once daily

10 to 20 days, every 3 to 6 months

Single source. The site denies vendor affiliations and lists suppliers.

Pinealon

Pinealon at a glance

What is Pinealon?

Pinealon structure and chemistry